Compare BGSI & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGSI | SUPN |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | Canada | United States |
| Employees | 13449 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | N/A | 2010 |
| Metric | BGSI | SUPN |
|---|---|---|
| Price | $90.10 | $44.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $157.00 | $61.60 |
| AVG Volume (30 Days) | 26.4K | ★ 580.0K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $35.07 | $22.70 |
| Revenue Next Year | $8.01 | $19.14 |
| P/E Ratio | $231.07 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $90.64 | $31.16 |
| 52 Week High | $183.10 | $59.68 |
| Indicator | BGSI | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 28.57 | 39.82 |
| Support Level | N/A | $43.67 |
| Resistance Level | $110.36 | $52.36 |
| Average True Range (ATR) | 3.36 | 1.35 |
| MACD | -0.50 | 0.05 |
| Stochastic Oscillator | 0.00 | 43.95 |
Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. he Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority. The company has majority of its sales from USA.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.